Gilead Sciences (GILD) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Gilead Sciences (GILD) do?
Gilead Sciences Inc (GILD) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures prescription antiviral medications for HIV and viral hepatitis alongside cell therapies for complex cancers. Produces specialized antiviral therapies that treat the majority of the global population living with HIV. It is worth $206.55B on the market and sold $31.06B over the last year.
- Market cap
- $206.55B
- P/E ratio
- None (reported a loss)
- Annual sales
- $31.06B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 16, 2026
Brands and businesses behind GILD
- Biktarvy: Treats HIV infection as a daily single tablet and generates over half of Gilead's pharmaceutical sales.
- Descovy: Provides HIV treatment and pre-exposure prevention therapy through direct commercial pharmacy sales.
- Veklury: Treats severe COVID-19 infections intravenously in hospital inpatient settings.
- Trodelvy: Treats metastatic breast and urothelial cancer, earning revenue through specialized oncology sales.
- Yescarta: Provides individualized cell therapy for large B-cell lymphoma manufactured specifically for each patient.
- Epclusa: Cures chronic hepatitis C across all major genotypes, generating revenue from direct prescription sales.
GILD’s flags, in plain English
Each flag is a number from Gilead Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Wide Gross Margin
Gross margin of 80% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Cheap on Cash Flow
Priced at 15 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Pays You to Hold
Pays a 1.98% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.
Debt Is Driving
Heavy debt, 201% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about GILD
How big is Gilead Sciences?
Gilead Sciences’ market cap is $206.55B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $31.06B: what customers paid the company over the last year, before any costs.
What is GILD’s P/E ratio?
GILD has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with GILD?
More than half of the company's total revenue depends on a single HIV drug called Biktarvy. That is one risk on Gilead Sciences’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Gilead Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GILD’s filings on SEC.gov. The Margin Monkey is research, not advice.
